Laquinimod

Sök

Safety and Biodistribution of Topical Laquinimod, an Immunomodulator Targeting Aryl Hydrocarbon Receptor: The LION Study

El Feky D, Akhavanrezayat A, Mobasserian A, Khan H, Elaraby O, Yavari N, Halim MS, Tram Tran AN, Khatri A, Kirimli GU, Tuong Than NT, Vahtola E, Törngren M, Hung JH, Moussa M, DeBoer C, Mruthyunjaya P, Smith S, Or C, Kabeel M, Serag Y, Do DV, Urtti A, Nguyen QD.

Ophthalmol Sci. 2026 Apr 3;6(6):101186. doi: 10.1016/j.xops.2026.101186. eCollection 2026 Jun

Laquinimod treatment attenuates EAU by inhibiting both the inductive and effector phases in an APC-dependent manner

Xu B, Mattapallil MJ, Jia X, Tang J, Horai R, Caspi RR, Gery I.

bioRxiv [Preprint]. 2025 May 25:2025.05.20.654165. doi: 10.1101/2025.05.20.654165

Topical Ocular Laquinimod in Development for Inflammatory Eye Disorders

Garhöfer G, Bondesson E, Ekberg P, Schmidl D, Tuvesson H, Törngren M, Vahtola E

Presenterades på International Ocular Inflammation Society (IOIS) 2023 Meeting i Berlin, 6-9 September, 2023

Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS

Rothhammer V, Kenison J, Li Z, Tjon E, Takenaka MC, Chao C-C, de Lima K A, Borucki M, Kaye J an Quintana FJ

Neurol Neuroimmunol Neuroinflamm 2021 Jan 6;8(2):e946

CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis

Comi G, Dadon Y, Sasson N, Steinerman JR, Knappertz V, Vollmer TL, Boyko A, Vermersch P, Ziemssen T, Montalban X, Lublin FD, Rocca MA, Volkinshtein R, Rubinchick S, Halevy N, Filippi M.

Mult Scler. 2022 Apr;28(4):608-619. doi: 10.1177/13524585211032803. Epub 2021 Aug 11

Laquinimod arrests development of experimental autoimmune uveitis (EAU) and inhibits related immune processes, in the context of altered gut microbiota

Xu B, Jia X, Tang J, Caspi RR, Gery I

J Immunol. 2020;204 (1 Supplement)

Laquinimod arrests development of experimental autoimmune uveitis (EAU) and inhibits related immune processes, in the context of altered gut microbiota

Biying Xu, Xiuzhi Jia, Jihong Tang, Rachel R Caspi and Igal Gery,

J Immunol May 1, 2020, 204 (1 Supplement) 150.18

Magnetic Resonance Spectroscopy Evaluation of Neuronal Integrity and Astrocytosis in a Phase 2 Study of Laquinimod as a Treatment for Huntington Disease (LEGATO-HD)

Blair R. Leavitt, Ralf Reilmann, Mark Forrest Gordon, Karen E. Anderson, Andrew Feigin, Sarah J. Tabrizi, Julie C. Stout, Paola Piccini, Bretta Russell-Schulz, Alex L. Mackay, Beth Borowsky, Gail Rynkowski, Rita Volkinshtein, Juha-Matti Savola, Michael R. Hayden

Presenterat på den internationella kongressen ”Parkinson’s disease and movement disorders”, 2019

Brain MRI Volume Changes after 12 months laquinimod treatment of Huntington disease (LEGATO-HD)

Ralf Reilmann, Mark Forrest Gordon, Karen E. Anderson, Andrew Feigin, Sarah J. Tabrizi5, Blair R. Leavitt, Julie C. Stout, Paola Piccini, Nicola Hobbs, Richard Manber, Beth Borowsky, Gail Rynkowski, Rita Volkinshtein, Juha-Matti Savola and Michael Hayden

Presenterat på den internationella kongressen ”Parkinson’s disease and movement disorders”, 2019

Quantitative Motor (Q-Motor) Assessments Suggest a Beneficial Central Effect of Laquinimod in a Phase II Study in Huntington Disease (LEGATO-HD)

Ralf Reilmann, Mark Forrest Gordon, Robin Schubert, Karen E. Anderson, Andrew Feigin, Sarah J. Tabrizi, Blair R. Leavitt, Julie C. Stout, Paola Piccini, Beth Borowsky, Gail Rynkowski, Rita Volkinshtein, Juha-Matti Savola, Michael R. Hayden

Presenterat på den internationella kongressen ”Parkinson’s disease and movement disorders”, 2019